Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial
Alimentary Pharmacology & Therapeutics2018Vol. 47(11), pp. 1453–1463
Citations Over TimeTop 10% of 2018 papers
Neville D. Yeomans, David Y. Graham, M. Elaine Husni, Daniel H. Solomon, Tyler Stevens, John J. Vargo, Q. Wang, L Wiśniewski, Kathy Wolski, Jeffrey Borer, Peter Libby, A. Michael Lincoff, Thomas F. Lüscher, Weihang Bao, Chris Walker, Steven E. Nissen, the PRECISION investigators
Abstract
Arthritis patients taking NSAIDs plus esomeprazole have infrequent clinically significant gastrointestinal events. Co-prescribed with esomeprazole, celecoxib has better overall GI safety than ibuprofen or naproxen at these doses, despite treatment with low-dose aspirin or corticosteroids.
Related Papers
- → Evaluation of anti-inflammatory and ulcerogenic potential of zinc–ibuprofen and zinc–naproxen complexes in rats(2017)31 cited
- → The effect of tableting on the release characteristics of naproxen and ibuprofen microcapsules(1993)13 cited
- Comparative evaluation of Celecoxib (a Cox-2 inhibitor) versus Ibuprofen in control of pain due to Acute Apical Periodontitis(2006)
- Celecoxib vs ibuprofen in treating osteoarthritis(2002)